Evolus
Evolus medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. They focus on the self-pay aesthetic market and their first product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. They believe they will offer physicians and patients a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. They believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. We have completed the clinical development program for DWP-450 for the treatment of moderate to severe glabellar lines ("frown lines") between the eyebrows in the US, EU, and Canada. The FDA issued a PDUFA date of May 15, 2018, for completion of its review of our BLA. We submitted an MAA to the EMA and a decision is expected by the second half of 2018. They have also submitted an NDS in Canada. They have an exclusive distribution license to DWP-450 from Daewoong Pharmaceuticals Co.
Evolus medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. They focus on the self-pay aesthetic market and their first product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. They believe they will offer physicians and patients a compelling value proposition with DWP-450. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader and the only known approved 900 kDa botulinum toxin type A complex in the United States. They believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. We have completed the clinical development program for DWP-450 for the treatment of moderate to severe glabellar lines ("frown lines") between the eyebrows in the US, EU, and Canada. The FDA issued a PDUFA date of May 15, 2018, for completion of its review of our BLA. We submitted an MAA to the EMA and a decision is expected by the second half of 2018. They have also submitted an NDS in Canada. They have an exclusive distribution license to DWP-450 from Daewoong Pharmaceuticals Co.
Evolus has raised $125M across 1 round. Its most recent round was a Post-IPO Debt of $125M in Dec 2021. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Evolus is featured in
Similar companies
ALZpath is a biotech organization that offers innovative diagnostic options for Alzheimer's disease.
Reme-D is a cutting-edge technology company that has patented technology, which is revolutionizing healthcare in areas with limited resources by providing cost-effective and efficient disease testing systems. This ensures that everyone has equal access to essential medical diagnostics.
Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.
Lyora Therapeutics develops genetic medicines for inherited retinal diseases that currently have no treatment.
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics. The company is creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.
Kuehnle Agrosystems, Inc. specializes in biotech research and development of plant-based systems used for producing biologically active compounds. Originally known as Kuehnle Agrosystems Company, LLC, the company was established in 2007 and is located in Honolulu, Hawaii.
ETI have fostered a protected, novel clinical gadget that eliminates galectin-3 from human blood. The gadget eliminates both bound and free galectin-3 from the course, offering another treatment choice that is less obtrusive and has less aftereffects than different treatments. The single-use apheresis segment specifically eliminates Galectin-3 from the body. It contains an exclusive, profoundly powerful catching particle and is underlying an organization that medical clinics definitely know how to utilize.
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Tenon Medical, a biotech firm specializing in enhancing surgical solutions for the SI joint, was established in 2012 in Morgan Hill, California.
Aptevo Therapeutics is a biotech company based in Seattle that focuses on developing new treatments for cancer and blood disorders. They use a special technology called ADAPTIR™ to improve outcomes for cancer patients. The company is known for its supportive work environment, culture of innovation, and unique platform technology. As a result, Aptevo has been able to attract talented individuals with experience in other leading biotech companies such as Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.